US 11504390
Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
granted A61KA61K31/7105A61K38/00
Quick answer
US patent 11504390 (Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/7105, A61K38/00, A61P, A61P3/06